Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Patients with oropharyngeal cancers who were treated with proton therapy, compared to traditional radiation therapy saw a significant survival benefit, according to the findings from a phase III trial led by researchers at the University of Texas MD Anderson Cancer Center.

December 19, 2025

Vol.51 No.46

Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.

October 31, 2025

Vol.51 No.40

Drugs & Targets

EU CHMP issues two positive opinions for Keytruda

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted two positive opinions for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.

September 26, 2025

Vol.51 No.35

In Brief

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

The National Institute of Dental and Craniofacial Research awarded a $3 million grant to researchers from Henry Ford Health + Michigan State University Health Sciences to study new treatments for patients who have head-and-neck cancer caused by HPV.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Mayo Clinic researchers have established the world’s first biobank of human salivary gland tissue-organoids to study chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands that affects millions.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab (Keytruda) added to standard-of-care therapy improved survival for patients with locally advanced head-and-neck cancer.

May 02, 2025

Vol.51 No.17

Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

YOU MAY BE INTERESTED IN

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

EC approves Keytruda combination for a head-and-neck indication

EU CHMP issues two positive opinions for Keytruda

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

Renew today!

Subscriber content

Never miss an issue!

Login